166 related articles for article (PubMed ID: 12759413)
1. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.
Zeis M; Siegel S; Wagner A; Schmitz M; Marget M; Kühl-Burmeister R; Adamzik I; Kabelitz D; Dreger P; Schmitz N; Heiser A
J Immunol; 2003 Jun; 170(11):5391-7. PubMed ID: 12759413
[TBL] [Abstract][Full Text] [Related]
2. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
Schmidt SM; Schag K; Müller MR; Weck MM; Appel S; Kanz L; Grünebach F; Brossart P
Blood; 2003 Jul; 102(2):571-6. PubMed ID: 12576330
[TBL] [Abstract][Full Text] [Related]
3. Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies.
Siegel S; Wagner A; Friedrichs B; Wendeler A; Wendel L; Kabelitz D; Steinmann J; Barsoum A; Coggin J; Rohrer J; Dreger P; Schmitz N; Zeis M
J Immunol; 2006 Jun; 176(11):6935-44. PubMed ID: 16709854
[TBL] [Abstract][Full Text] [Related]
4. Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model.
Siegel S; Wagner A; Schmitz N; Zeis M
Br J Haematol; 2003 Sep; 122(6):911-4. PubMed ID: 12956760
[TBL] [Abstract][Full Text] [Related]
5. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
[TBL] [Abstract][Full Text] [Related]
6. Characterization of BAX inhibitor-1 as a novel leukemia-associated antigen.
Schmidt SM; König T; Bringmann A; Held S; von Schwarzenberg K; Heine A; Holderried TA; Stevanovic S; Grünebach F; Brossart P
Leukemia; 2009 Oct; 23(10):1818-24. PubMed ID: 19609282
[TBL] [Abstract][Full Text] [Related]
7. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies.
Siegel S; Wagner A; Kabelitz D; Marget M; Coggin J; Barsoum A; Rohrer J; Schmitz N; Zeis M
Blood; 2003 Dec; 102(13):4416-23. PubMed ID: 12869512
[TBL] [Abstract][Full Text] [Related]
8. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA.
Heiser A; Maurice MA; Yancey DR; Wu NZ; Dahm P; Pruitt SK; Boczkowski D; Nair SK; Ballo MS; Gilboa E; Vieweg J
J Immunol; 2001 Mar; 166(5):2953-60. PubMed ID: 11207244
[TBL] [Abstract][Full Text] [Related]
9. [Experimental study on activating antileukemic T cells by vaccination with dendritic cells pulsed with survivin].
Zhang XH; Xia LH; Liu ZP; Wei WN; Hu Y; Song SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):66-9. PubMed ID: 12667293
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas.
Ciesielski MJ; Apfel L; Barone TA; Castro CA; Weiss TC; Fenstermaker RA
Cancer Immunol Immunother; 2006 Dec; 55(12):1491-503. PubMed ID: 16485128
[TBL] [Abstract][Full Text] [Related]
11. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA.
Koido S; Kashiwaba M; Chen D; Gendler S; Kufe D; Gong J
J Immunol; 2000 Nov; 165(10):5713-9. PubMed ID: 11067929
[TBL] [Abstract][Full Text] [Related]
12. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic.
Ciesielski MJ; Ahluwalia MS; Munich SA; Orton M; Barone T; Chanan-Khan A; Fenstermaker RA
Cancer Immunol Immunother; 2010 Aug; 59(8):1211-21. PubMed ID: 20422411
[TBL] [Abstract][Full Text] [Related]
13. Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes.
Müller MR; Grünebach F; Nencioni A; Brossart P
J Immunol; 2003 Jun; 170(12):5892-6. PubMed ID: 12794115
[TBL] [Abstract][Full Text] [Related]
14. Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells.
Meyer zum Büschenfelde C; Nicklisch N; Rose-John S; Peschel C; Bernhard H
J Immunol; 2000 Oct; 165(7):4133-40. PubMed ID: 11034426
[TBL] [Abstract][Full Text] [Related]
15. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
Yang S; Linette GP; Longerich S; Haluska FG
J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
[TBL] [Abstract][Full Text] [Related]
16. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides.
Schmitz M; Diestelkoetter P; Weigle B; Schmachtenberg F; Stevanovic S; Ockert D; Rammensee HG; Rieber EP
Cancer Res; 2000 Sep; 60(17):4845-9. PubMed ID: 10987296
[TBL] [Abstract][Full Text] [Related]
17. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients.
Andersen MH; Pedersen LO; Becker JC; Straten PT
Cancer Res; 2001 Feb; 61(3):869-72. PubMed ID: 11221872
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA
Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666
[TBL] [Abstract][Full Text] [Related]
19. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro.
Heiser A; Dahm P; Yancey DR; Maurice MA; Boczkowski D; Nair SK; Gilboa E; Vieweg J
J Immunol; 2000 May; 164(10):5508-14. PubMed ID: 10799919
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.
Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL
J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
